Radius Health, Inc.
RDUS
|
$17.71
0.4%
30K
|
Health Technology
(0.0% 1d) (-7.5% 1m) (-40.2% 1y) (0.0% 2d) (-2.9% 3d) (-5.7% 7d) (29.02% volume)
Earnings Calendar: 2024-01-04
Market Cap: $ 492,022,071
http://www.radiuspharm.com
Sec Filling | Patents | 383 employees
(US) Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
breast cancer cancer education endocrine hormone urea women osteoporosis elacestrant
Drugs
Tymlos (abaloparatide)add to watch list Paper trade email alert is off
Press-releases
Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -1.65%
H: 0.98%
C: 0.69%
osteoarthritis congress world presentation tymlos
Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date
Published: 2024-03-14 (Crawled : 21:00) - globenewswire.com
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -1.57%
H: 3.98%
C: 2.6%
announcement results
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Published: 2023-09-20 (Crawled : 15:00) - prnewswire.com
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: 0.07%
H: 2.72%
C: -0.85%
orserdu breast cancer treatment her2-
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2
Published: 2023-07-21 (Crawled : 13:00) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: 0.21%
H: 0.67%
C: -0.98%
orserdu chmp her2 approval positive group treatment
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
Published: 2023-05-26 (Crawled : 11:00) - prnewswire.com
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: 0.87%
H: 0.69%
C: -0.27%
orserdu breast asco cancer group study
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -0.29%
H: 1.97%
C: 0.62%
elacestrant breast asco cancer group meeting
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 12:20) - prnewswire.com
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval cancer orserdutm elacestrant esr1 mutation elascestrant her2- her2 metastatic breast cancer
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 12:20) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval therapeutics cancer elacestrant esr1 mutation elascestrant orserdu her2- her2 metastatic breast cancer
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -1.99%
H: 2.44%
C: 0.48%
treatment fda breast approval therapeutics cancer orserdutm elacestrant esr1 mutation elascestrant her2- her2 metastatic breast cancer
Radius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Published: 2022-12-20 (Crawled : 22:00) - biospace.com/
RDUS | $17.71 0.4% 30K
|
Health Technology
|
| O: -0.7%
H: 3.3%
C: 1.73%
tymlos treatment fda risk bone approval osteoporosis
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000899243-22-030031 | 4 | 2022-08-30 | 2022-08-11 | Sell | U | 8733538 | 0 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 63% | 37% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
WHLM | $6.61 30.12% 400K
|
Commercial Services
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Last 48 Hours Insiders Buying
MEGI | $11.97 -0.08% 42K
|
|
00:30
CTRN P 29000 | $22.445 0.97% 16K
|
Retail Trade
|
22:00
CONN | $3.7 12K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.615 -0.11% 110K
|
Finance
|
17:30
RMCF | $3.54 410
|
Consumer Non-Durables
|
20:10